The HDAC1-3 inhibitor entinostat, in combination with BRAF/MEK inhibitors, synergistically increased apoptosis induction in BRAF-mutant melanoma cells, thus killing cells that would have survived BRAF/MEK inhibitors alone. Here, BRAF is linked to melanoma.